Global Burden of Alzheimer's Disease and Other Dementias during 1990-2021: A Global Burden of Disease and Risk Factors Study 2021-Based Study.

IF 3.2 3区医学 Q2 CLINICAL NEUROLOGY

Neuroepidemiology Pub Date : 2025-01-21 DOI:10.1159/000543578

Renxi Wang

{"title":"Global Burden of Alzheimer's Disease and Other Dementias during 1990-2021: A Global Burden of Disease and Risk Factors Study 2021-Based Study.","authors":"Renxi Wang","doi":"10.1159/000543578","DOIUrl":null,"url":null,"abstract":"Introduction: In most countries and territories, current data on the burden of Alzheimer's disease (AD) and other dementias are lacking. We aimed to assess the trends, burden, and inequalities of AD and other dementias at global, regional, and national level from 1990 to 2021.Methods: The data on disease burden of AD and other dementias during 1990-2021 were extracted from Global Burden of Disease and Risk Factors Study 2021 (GBD 2021). Average annual percentage changes (AAPCs) of age-standardized prevalence, mortality, and disability-adjusted life-years (DALYs) were estimated as an indicator to evaluate the healthcare system.Result: The global age-standardized prevalence of AD and other dementias increased from 672 (95% uncertainty interval: 589 to 764) per 100,000 population in 1990 to 694 (603 to 794) per 100,000 population in 2021, with AAPCs of 0.09% (95% confidence interval: 0.06% to 0.11%). However, age-standardized mortality did not change (AAPCs: 0.00% [-0.01% to 0.02%]) and age-standardized DALYs slightly increased from 446 (206 to 958) to 451 (213 to 950) per 100,000 population (AAPCs: 0.01% [0.00% to 0.03%]). While the highest prevalence remained in population aged 65-69 and the countries with a high-middle sociodemographic index (SDI) such as East Asia (e.g., China), the highest mortality and DALYs were found in population aged 65-69 and the countries with a low-middle SDI such as South Asia (e.g., India). High fasting plasma glucose ranked the highest risk factor for DALYs during 1990-2021.Conclusion: The global increased prevalence of AD and other dementias may partly be attributed to population aged 65-69 in the countries with a high-middle SDI (e.g., China), whereas mortality and DALY ratio of population aged 65-69 from the countries with a low-middle SDI (e.g., India) is most significantly growing. Controlling of high fasting plasma glucose may be needed for the reduction of DALYs from AD and other dementias.","PeriodicalId":54730,"journal":{"name":"Neuroepidemiology","volume":" ","pages":"1-12"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuroepidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000543578","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: In most countries and territories, current data on the burden of Alzheimer's disease (AD) and other dementias are lacking. We aimed to assess the trends, burden, and inequalities of AD and other dementias at global, regional, and national level from 1990 to 2021.

Methods: The data on disease burden of AD and other dementias during 1990-2021 were extracted from Global Burden of Disease and Risk Factors Study 2021 (GBD 2021). Average annual percentage changes (AAPCs) of age-standardized prevalence, mortality, and disability-adjusted life-years (DALYs) were estimated as an indicator to evaluate the healthcare system.

Result: The global age-standardized prevalence of AD and other dementias increased from 672 (95% uncertainty interval: 589 to 764) per 100,000 population in 1990 to 694 (603 to 794) per 100,000 population in 2021, with AAPCs of 0.09% (95% confidence interval: 0.06% to 0.11%). However, age-standardized mortality did not change (AAPCs: 0.00% [-0.01% to 0.02%]) and age-standardized DALYs slightly increased from 446 (206 to 958) to 451 (213 to 950) per 100,000 population (AAPCs: 0.01% [0.00% to 0.03%]). While the highest prevalence remained in population aged 65-69 and the countries with a high-middle sociodemographic index (SDI) such as East Asia (e.g., China), the highest mortality and DALYs were found in population aged 65-69 and the countries with a low-middle SDI such as South Asia (e.g., India). High fasting plasma glucose ranked the highest risk factor for DALYs during 1990-2021.

Conclusion: The global increased prevalence of AD and other dementias may partly be attributed to population aged 65-69 in the countries with a high-middle SDI (e.g., China), whereas mortality and DALY ratio of population aged 65-69 from the countries with a low-middle SDI (e.g., India) is most significantly growing. Controlling of high fasting plasma glucose may be needed for the reduction of DALYs from AD and other dementias.

查看原文本刊更多论文

1990-2021年阿尔茨海默病和其他痴呆症的全球负担：一项基于2021年的全球疾病负担和风险因素研究

在大多数国家和地区，目前缺乏关于阿尔茨海默病（AD）和其他痴呆症负担的数据。我们的目的是评估1990年至2021年全球、地区和国家层面阿尔茨海默病和其他痴呆症的趋势、负担和不平等。方法：从全球疾病负担和危险因素研究2021 （GBD 2021）中提取1990-2021年AD和其他痴呆的疾病负担数据。估计年龄标准化患病率、死亡率和残疾调整生命年（DALYs）的平均年百分比变化（AAPCs）作为评估医疗保健系统的指标。结果：全球AD及其他痴呆年龄标准化患病率从1990年的每10万人672例（95%不确定区间：589 ~ 764例）上升至2021年的每10万人694例（603 ~ 794例），AAPCs为0.09%（95%置信区间：0.06% ~ 0.11%）。然而，年龄标准化死亡率没有变化（AAPCs: 0.00%(-0.01%至0.02%)），年龄标准化DALYs从每10万人446（206至958）轻微增加到451(213至950)（AAPCs: 0.01%(0.00%至0.03%)）。虽然65-69岁人口和社会人口指数中高的国家（如东亚（如中国））的患病率仍然最高，但65-69岁人口和社会人口指数中低的国家（如南亚（如印度））的死亡率和伤残调整生命年最高。在1990-2021年期间，高空腹血糖是DALYs的最高危险因素。结论：全球阿尔茨海默病和其他痴呆症患病率的增加可能部分归因于中高SDI国家（如中国）65-69岁人口，而中低SDI国家（如印度）65-69岁人口的死亡率和DALY比率增长最为显著。控制高空腹血糖可能需要减少阿尔茨海默病和其他痴呆的DALYs。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Neuroepidemiology 医学-公共卫生、环境卫生与职业卫生

CiteScore

9.90

自引率

1.80%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Neuroepidemiology'' is the only internationally recognised peer-reviewed periodical devoted to descriptive, analytical and experimental studies in the epidemiology of neurologic disease. The scope of the journal expands the boundaries of traditional clinical neurology by providing new insights regarding the etiology, determinants, distribution, management and prevention of diseases of the nervous system.